Exogenus Therapeutics Taps Lonza to Develop a GMP-Compliant Process for Lead Exosome-Based Candidate
Exogenus Therapeutics and Lonza agreed to collaborate on the development of Exo-101, Exogenus’ exosome-based lead candidate. The company specializes in the development of therapeutics based on ...
IB [email protected] ReiThera to Showcase Innovative Viral Vector Platforms at ESGCT 2025Rome, Italy – September 30 2025 – ReiThera Srl, the Italian leading Contract Development ...
GentiBio, Inc., an emerging biotherapeutics company developing best-in-class engineered regulatory T cells programmed to treat autoimmune, alloimmune, autoinflammatory, and allergic diseases, and ...
The launch of the GMP PSXi013 iPSC Master Cell Bank marks a pivotal moment in Pluristyx's ongoing mission to accelerate the development of stem cell therapies. By providing a high-quality, low-passage ...
Our Bureau, Bengaluru Monday, September 29, 2025, 14:15 Hrs [IST] ...
Small biotechs in early development of cell therapies are often surprised by the strictness of commercial manufacturing standards. That’s the view of Luděk Sojka, PhD, CEO of contract developer and ...
VectorBuilder, a global leader in the gene delivery space, has won two prestigious awards at the Asia-Pacific Cell and Gene ...
VANCOUVER, British Columbia, Jan. 21, 2025 (GLOBE NEWSWIRE) -- HYTN Innovations Inc. (CSE: HYTN, FSE: 85W0, OTC PINK: HYTNF) (“HYTN” or the “Company”), a company specializing in pharmaceutical-grade ...
BioIVT, a global research partner and biospecimen solutions provider for drug and diagnostic development, today announced the launch of VivoSTART™ Cryopreserved GMP Leukopaks. The GMP-compliant ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback